Janssen-Cilag International NV (JNJ) Release: VOKANAMET (Canagliflozin And Metformin Fixed Dose Combination) Receives Positive CHMP Opinion Recommending Approval In The European Union For The Treatment Of Adults With Type 2 Diabetes
2/21/2014 8:45:33 AM
BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation in the European Union for the medicinal product VOKANAMETTM, a fixed-dose therapy combining canagliflozin and immediate release metformin in a single tablet, intended for the treatment of type 2 diabetes mellitus. Canagliflozin is currently available as INVOKANATM following approval in the European Union in November 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by